Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma

Published:2017 Issue: Volume:2017 Page:1-12
ISSN:0962-9351
Container-title:Mediators of Inflammation
language:en
Short-container-title:Mediators of Inflammation

Author:

Yoo So Young¹²³⁴^ORCID,Badrinath Narayanasamy¹²^ORCID,Woo Hyun Young³⁴,Heo Jeong³⁴^ORCID

Affiliation:

1. BIO-IT Foundry Technology Institute, Pusan National University, Busan 46241, Republic of Korea

2. Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan 50612, Republic of Korea

3. Department of Internal Medicine, College of Medicine, Pusan National University and Medical Research Institute, Yangsan 50612, Republic of Korea

4. Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea

Abstract

Hepatocellular carcinoma is highly refractory cancer which is resistant to conventional chemotherapy and radiotherapy, carrying a dismal prognosis. Although many anticancer drugs have been developed for treating HCC, sorafenib is the only effective treatment, but it only prolongs survival duration for about 3 months. Recently, oncolytic virotherapy has shown promising results in treating HCCs and the effects can be more enhanced by adopting immune modulatory molecules. This review discusses the current status of treating HCC and the effective strategy of oncolytic virus-based immunotherapy for the treatment of HCCs.

Funder

Pusan National University Hospital

Publisher

Hindawi Limited

Subject

Cell Biology,Immunology

Link

http://downloads.hindawi.com/journals/mi/2017/5198798.pdf

Reference94 articles.

1. Management of hepatocellular carcinoma: An update

2. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

3. Hepatocellular carcinoma pathogenesis: from genes to environment